The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Protagonist Therapeutics Inc shares valued at $80,776 were sold by Ali Asif on Apr 22 ’25. At $46.00 per share, Ali Asif sold 1,756 shares. The insider’s holdings dropped to 61,065 shares worth approximately $2.91 million following the completion of this transaction.
Also, Waddill William D. sold 4,000 shares, netting a total of over 217,000 in proceeds. Following the sale of shares at $54.25 each, the insider now holds 13,130 shares.
Before that, WILLIAM D WADDILL had added 4,000 shares to its account. In a trade valued at $219,120, the Director bought Protagonist Therapeutics Inc shares for $54.78 each.
As published in their initiating research note from Goldman on December 06, 2024, Protagonist Therapeutics Inc [PTGX] has been a Neutral and the price target has been revised to $47. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in early December. As of November 05, 2024, Wedbush has initiated its “an Outperform” rating for PTGX. Earlier on September 24, 2024, TD Cowen initiated its rating. Their recommendation was “a Buy” for PTGX stock.
Analyzing PTGX Stock Performance
During the last five days, there has been a surge of approximately 3.84%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 23.26%. Shares of the company reached a 52-week high of $60.60 on 03/12/25 and a 52-week low of $33.70 on 02/25/25.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
According to the 24-hour chart, there is a support level at 46.12, which, if violated, would cause prices to drop to 44.67. In the upper region, resistance lies at 48.34. The next price resistance is at 49.11. RSI (Relative Strength Index) is 59.14 on the 14-day chart, showing neutral technical sentiment.
